Related Experiment Video
Updated: Aug 9, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Childhood poisoning involving transdermal nicotine patches
A Woolf1, K Burkhart, T Caraccio
1Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Children's Hospital, Boston, Massachusetts; Massachusetts Poison Control System, Boston, Massachusetts, USA.
Insights
Unintentional exposure to transdermal nicotine patches (TNP) in children typically involves used patches and results in mild, transient symptoms. Most cases require only basic decontamination and supportive care, with full recovery reported.
Area of Science:
- Toxicology
- Pediatric Emergency Medicine
- Public Health Surveillance
Background:
- Transdermal nicotine patches (TNP) are used for smoking cessation.
- Accidental pediatric exposure to TNPs can occur through dermal contact or ingestion.
- Understanding the risks associated with TNP exposure in children is crucial for public health and clinical management.
Observation:
- A prospective case series analyzed 36 TNP exposures in children aged 0-15 years reported to poison centers over 24 months.
- Exposures involved dermal contact with intact or used patches (18 cases) or oral exposure via biting/swallowing patch components (18 cases).
- No specific brand of TNP was associated with increased symptom severity.
Findings:
- Symptomatic children (39%) experienced gastrointestinal distress, weakness, dizziness, or localized rashes.
- Symptom development after dermal exposure correlated with an estimated nicotine dose of ≥0.10 mg.
- Ten children required emergency department visits, and two were hospitalized, with all patients making a full recovery.
Implications:
- Unintentional TNP exposures in young children are often associated with used patches and are generally transient.
- Management primarily involves skin decontamination and supportive care.
- Continued surveillance of inadvertent TNP exposures in children is recommended to validate these findings and inform safety guidelines.
Objective:
To describe the circumstances, medical complications, and outcomes of children exposed to a transdermal nicotine patch (TNP).
Design:
Prospective case series; postmarketing surveillance study over a 24-month period.
Setting:
Thirty-four United States poison centers. Patients. Children 0 to 15 years old exposed to a TNP.
Interventions:
None.
Outcome Measures:
Exposure circumstances, symptoms and signs of toxicity, complications, disposition, and hospital length of stay.
Results:
Reports were received concerning 36 exposures to TNP in children younger than 16 years old (mean: 3 years old). Eighteen of these TNP exposures were dermal; 18 additional children had bitten, chewed, or swallowed part of a patch. All four commercial brands of TNP were represented; no brand was associated with more symptoms or an increased severity of illness. Fourteen children (39%) developed symptoms, including gastrointestinal distress (nausea, vomiting, diarrhea, abdominal pain), weakness, dizziness, or localized rashes. Occurrence of symptoms after a dermal exposure to a TNP was associated with an estimated nicotine dose >/=.10 mg (>/=.01 mg/kg body weight). Ten children were seen in the emergency department; two were admitted overnight. All recovered fully.
Conclusions:
In this series, unintentional exposures to TNPs among young children usually involved used patches, were transient (<20 minutes duration), and required only skin decontamination and supportive care. Continued monitoring of inadvertent childhood exposures to TNPs is recommended to confirm these observations.
More Related Videos
Related Concept Videos
Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Prevention of Further Absorption of Poison
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Toxidromes: Clinical Features
Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical Poisoning: Treatment Strategies

